FDA, EMA propose more efficient approach to drug development

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/thomas-bethge)
(Image: iStock/thomas-bethge)

Related tags: Draft guidance, Clinical trial, Food and drug administration, Pharmacology

The US Food and Drug Administration (FDA) has released a new draft guidance as part of its stated commitment to assist sponsors and expedite drug development for rare pediatric diseases.

The draft guidance has been in development since 2011 and is the result of collaboration between the FDA and the European Medicines Agency (EMA). Together, the agencies gathered feedback from patient, scientific, and drug development communities to develop “Gaucher disease: A strategic collaborative approach from EMA and FDA​.”

The document was released today as an FDA guidance, using Gaucher disease as a model. However, the described approach could be extended to other rare pediatric diseases, according to the FDA.

The proposed approach, if adopted by sponsors, has the potential to ultimately help speed products to market by minimizing the time it takes to conduct drug studies​,” FDA trade press officer Jeremy Kahn told Outsourcing-Pharma.com.

Having an approach agreed upon by FDA and European regulators can facilitate collaboration among study sponsors and regulators and get studies started in a time efficient manner​,” he added.

As Kahn explained, the proposed strategy includes two elements: “the use of statistical models and simulations that may eliminate the need for certain clinical studies and the development of multi-arm, multi-sponsor clinical trials that reduce the total number of patients needed for placebo control groups​.”

The FDA previously encouraged the use of modeling and simulation​ as it unveiled its plans to implement aspects of the 21st​ Century Cures Act.

The FDA is seeking comments on the draft guidance for 60 days.

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers